Industry
Drug Manufacturers - General
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Loading...
Open
1.67
Mkt cap
23M
Volume
705K
High
1.71
P/E Ratio
-1.83
52-wk high
6.40
Low
1.54
Div yield
N/A
52-wk low
0.51
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 6:50 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 11:13 am
Portfolio Pulse from Benzinga Insights
September 11, 2024 | 1:30 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 8:20 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 3:03 pm
Portfolio Pulse from Vandana Singh
August 26, 2024 | 1:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 12:43 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.